A Novel Human Amphotropic Packaging Cell Line: High Titer, Complement Resistance, and Improved Safety  by RIGG, RICHARD J. et al.
VIROLOGY 218, 290–295 (1996)
ARTICLE NO. 0194
SHORT COMMUNICATION
A Novel Human Amphotropic Packaging Cell Line: High Titer,
Complement Resistance, and Improved Safety
RICHARD J. RIGG, JINGYI CHEN, JONATHAN S. DANDO, SEAN P. FORESTELL,
IVAN PLAVEC, and ERNST BO¨HNLEIN1
SyStemix, 3155 Porter Drive, Palo Alto, California 94304
Received December 20, 1995; accepted February 8, 1996
Successful retroviral-mediated gene therapy will depend on safe, efficient packaging cell lines for vector particle produc-
tion. Existing packaging lines for murine leukemia virus (MLV)-based vectors are predominantly derived from NIH/3T3 cells
which carry endogenous MLV sequences that could participate in recombination to form replication-competent retrovirus
(RCR). To identify cells devoid of such sequences, we screened genomic DNA from eight cell lines. DNA from the human 293
cell line did not cross-hybridize with MLV sequences, and these cells were able to secrete Gag particles after transfection. We
derived a stable amphotropic packaging cell line (called ProPak-A) in 293 cells in which the Gag-Pol and Env (packaging)
functions are expressed separately from a heterologous (non-MLV) promoter, to maximally reduce homology between
packaging and vector sequences. ProPak-A-based producer cells are efficient, yielding higher stable titers than PA317-
based producers. In addition, a vector that consistently gave rise to RCR in PA317 cells never resulted in detectable RCR
in ProPak-A-based producer cultures. We have also shown that ProPak-A-packaged particles are not inactivated by human
serum. Thus, the packaging cells we describe are as efficient and safer than the amphotropic packaging cells most commonly
used in clinical gene therapy work and are also more appropriate for in vivo gene delivery. q 1996 Academic Press, Inc.
The application of retroviral vector-mediated human cines are produced (44), and CHO cells which are used
to produce recombinant proteins (18). Mus dunni tail fi-gene therapy demands greater safety margins than ex-
perimental gene transfer. The majority of cell lines cur- broblasts were also included since these cells are report-
edly free of endogenous MLV sequences (20). Genomicrently available for stable production of retroviral vector
supernatants are derived from NIH/3T3 cells (6, 7, 21–24, DNA from NIH/3T3 cells, the basis for the majority of
existing packaging cell lines, hybridized very strongly28). Although packaging constructs have been designed
such that three recombination events are required for with both MLV-specific probes at low or high stringency
(Fig. 1; Table 2), consistent with a previous report (20).replication-competent retrovirus (RCR) generation (6, 7,
21–23, 28), the NIH/3T3 cells from which these lines Strong hybridization was also seen with CHO-K1 cell
DNA. In contrast, neither probe cross-hybridized with ge-were derived express endogenous murine leukemia vi-
rus (MLV) sequences (15) that can be packaged (36) nomic DNA from 293 (Fig. 1) or MRC-5 cells, even at low
stringency (Table 2). In addition, no cross-hybridizationand participate in recombination to form RCR (4, 42),
particularly in mass culture during large-scale clinical was seen with genomic DNA from M. dunni, MDCK (Fig.
1), Vero, or fox lung cells at high stringency (Table 2).vector production.
Table 1 summarizes the steps taken to generate and Fox lung and MRC-5 were discounted due to poor growth
and limited cell division potential, respectively, whichcharacterize the ProPak-A packaging cells. We initiated
our work by screening cell lines for endogenous MLV would preclude subcloning of stably transfected cells.
Thus, 293, MDCK, M. dunni, and Vero cells were identi-sequences. Genomic DNA from a variety of cell lines
was analyzed by Southern blot hybridization (35) using fied as candidate cell lines in which to derive packaging
cell lines.probes from the MLV long terminal repeat (LTR) or gag-
pol sequences (Table 2). We screened the following cell To decrease the probability of RCR formation, we con-
structed separate expression plasmids for gag-pol andlines: 293 cells that are used to produce adenoviral vec-
tors for clinical gene therapy applications (3) and retrovi- env, as previously described (6, 7, 21–23, 28). In contrast
to existing packaging constructs, however, we includedral vectors (31, 12), Vero and MRC-5 cells in which vac-
only the minimum genetic information required to encode
Gag-Pol and Env proteins. Figure 2 details the construc-1 To whom correspondence and reprint requests should be ad-
dressed. tion of Gag-Pol and Env expression plasmids.
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TABLE 1
ProPak-A Derivation Scheme
Objective Result
1. Identify cells lacking endogenous MLV-like sequences (candidate cell See Table 2; 293, Mus dunni TF, Vero, and MDCK candidate cells.
lines)
2. Prepare minimal gag-pol ORF by pcr; subclone into expression plasmids pCMV-gp (Fig. 2)
3. Prepare minimal amphotropic env ORF by pcr; subclone into expression pCMV*Ea (Fig. 2)
plasmid
4. Stably transfect gag-pol into candidate lines and screen for Gag 293 cells secrete Gag; chosen as base cell line
secretion
5. Stably transfect pCMV*Ea into 293 cells; isolate and characterize clones 293.Env clones
6. Stably transfect pCMV-gp into 293.Env cells; isolate and characterize ProPak-A clones
clones
7. Determine titer: end point, Table 3,
transduction efficiency Fig. 3
8. Determine sensitivity to human complement Fig. 4
To further identify the optimal cell line, sandwich ELISA from gag-pol-transfected 293 or M. dunni cells contained
Gag protein. In sharp contrast, no Gag was secretedassays were developed to detect Gag and Env proteins
by transfected Vero or MDCK cells, although Gag wasin transfected cells and supernatants. Plates were
present in the cell lysates (data not shown). This lack ofcoated with hybridoma culture supernatants from either
Gag secretion is puzzling since Vero-based producer83A25 (11) for Env or R187 (ATCC CRL 1912) for Gag.
cells can be established with the replication-competentCaptured proteins were detected with 79S-834 and 77S-
4070A virus (I. Plavec, unpublished results), but parallels227 antisera (Quality Biotech, Camden, NJ), respectively,
a report that HIV-1 Gag expressed in Vero cells alsoand horseradish peroxidase-conjugated anti-species an-
remains intracellular (9). The extended MLV Gag proteintibodies and 2,2-azinobis(3-ethylbenzothiazoline-6-sul-
sequence present in the replication-competent 4070A vi-fonic acid) (Pierce, Rockford, IL). The ability to produce
rus, but not in the Gag-Pol expression construct usedvector particles was assessed by transfection of a gag-
here, may be required for secretion of Gag particles frompol expression plasmid into candidate cell lines and se-
Vero or MDCK cells. We discounted Vero and MDCKlection of drug-resistant pools. Only the supernatants
cells as candidate cell lines and elected to derive pack-
aging cells based on human 293 cells because of the
TABLE 2 high transient transfection efficiency (31, 12).
Screening of Cell Lines for Cross-Hybridization
to MLV LTR or gag/pol Sequences
Endogenous MLV sequences
(hybridization)
Hybridization probe: LTR gag/pol
Wash stringency: Low High Low High
Cell lines tested
293 (ATCC CRL 1573) 0 0 0 0
MDCK (ATCC CCL 34) { 0 { 0
Mus dunni tail fibroblasts { 0 { 0
Vero (ATCC CCL 81) 0 0 { 0
FoLu (ATCC CCL 168) 0 0 { 0
MRC-5 (ATCC CCL 171) 0 0 0 0
NIH/3T3 (ATCC CRL 1658) // // // //
CHO-K1 (ATCC 61) // // // //
FIG. 1. Example of Southern blot analysis of cellular DNA for cross-Note. Hybridization signal strength: 0, none; {, weak; //, strong.
Probes: LTR (positions relative to cap site of genomic RNA), nucleotides hybridization with the MLV gag/pol probe after washing at low or high
stringency (see Table 2). P, pVH2 DNA digested with EcoRI and SalI.0232 (EcoRV) to 563 (PstI of 5* leader sequence); gag/pol, nucleotides
739 (PstI in gag) to 3705 (SalI in pol ). Stringency (657): Low, 500 mM Genomic DNA from 2, 293; 3, NIH/3T3; C, MDCK; or M, M. dunni tail
fibroblasts.Na/; High, 50 mM Na/. ATCC, American Type Culture Collection.
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FIG. 2. Diagram of expression plasmid (Gag-Pol and Env) structure showing the positions of selected restriction sites in parentheses. First, the
structural gene sequences were amplified by polymerase chain reaction (PCR) using the primers shown to obtain the open reading frames (ORFs)
from the initiation to the termination codons of the gag/pol or env genes flanked by NotI restriction sites, and the fragments were subcloned into
pBluescript (SK/) (Stratagene, La Jolla, CA). Oligonucleotide primers (Genosys Biotechnologies, Woodlands, TX) corresponding to the N-terminus
of the genes also placed the AUG in the ideal context for translation (19), and those corresponding to the C-terminus encoded a second in-frame
stop codon. The integrity of PCR products was verified by DNA sequencing. gag/pol: The ORF was amplified from the plasmid pVH-2, which
carries the infectious Moloney MLV sequence (27) using the primer pair 5*AAAAAAAAGCGGCCGCGCCGCCACCATGGGCCAGACTGTTACCAC3*
and 5*AAAAAAAAGCGGCCGCTCAttaGGGGGCCTCGCGGG3*. The underlined ATG is that of p15Gag (bases 621 to 623 (37)) and the codon in
lowercase corresponds to the pol stop codon (bases 5835 to 5837 (37)). The expression plasmid pCMV-gp, with the human cytomegalovirus
immediate early (CMV-IE) promoter, was constructed by inserting the gag-pol fragment into the pcDNA3 plasmid (Invitrogen, San Diego, CA) from
which the neomycin resistance expression cassette (DraIII to BsmI) had been deleted. Plasmids carrying the gag-pol ORF were propagated at 307
to prevent recombination (16). env: A contiguous amphotropic envelope sequence was constructed from p4070A (30) and amplified using the PCR
primers 5*TAATCTACGCGGCCGCCACCATGGCGCGTTCAACGCTC3* and 5*AATGTGATGCGGCCGCtcaTGGCTCGTACTCTATGG3*. The underlined
ATG corresponds to bases 37 to 39, and the stop codon (lowercase), bases 1998 to 2000 (30). The CMV promoter-Env expression plasmid pCMV*Ea
was created by insertion of the env ORF in place of the b-galactosidase gene of pCMVb (Clontech, Palo Alto, CA) modified by mutation of an
extraneous ATG in the SV40 intron to ACG (SD/SA*).
To derive packaging cells, we first introduced the from producer cell clones which had been transduced
with the LMTNL vector (10), in which an internal thymi-pCMV*Ea plasmid (Env) into 293 cells by cotransfection
(Profection kit, Promega, Madison, WI) with the pHA58 dine kinase promoter (T in vector name) drives the neo-
mycin phosphotransferase gene (N). End-point titers fromplasmid (33) conferring resistance to hygromycin B (250
mg/ml; Boehringer, Indianapolis, IN). Stably selected pop- ProPak-A-based producer cells were marginally higher
than those for our best PA317-based producer clone (Ta-ulations were stained with anti-Env antibody (83A25), and
individual Env-positive cells were isolated by automatic ble 3). In addition, the titers from ProPak-A.LMTNL pro-
ducer pools were stable when passaged for 3 monthscell deposition on a FACStar Plus (Becton Dickinson, San
Jose, CA). Three clones with the highest fluorescence in the absence of drug selection (data not shown).
While end-point titers are broadly used, transductionintensity were further characterized. All three yielded
equivalent titers upon transient cotransfection with gag- efficiency is a better measure of gene transfer potency
(13). However, the assay is laborious with vectors encod-pol and vector plasmids (data not shown).
Next, the pCMV-gp construct was stably transfected ing drug resistance genes. We therefore prepared
PA317- or ProPak-A-based producer cell populations car-into one of the three 293.Env clones by cotransfection
with the plasmid pSV2pac (43). Puromycin-resistant (1 rying a vector (LLySN) derived from the LXSN vector (26)
by insertion of the Lyt2 surface marker gene (39). Surfacemg/ml; Sigma, St. Louis, MO) clones were grown to con-
fluence, medium was exchanged, and supernatants were expression of the Lyt2 antigen allows simple, quantitative
determination of transduction efficiency by FACS (34).analyzed for Gag and Env content by ELISA. Clones were
identified (16 of 37) that secreted high levels of Gag Higher transduction efficiencies were achieved with su-
pernatants from two independently derived ProPak-A.and Env antigens (data not shown). Of these, six clones
produced virus in transient transfections at titers within LLySN populations than with supernatants from three
PA317.LLySN pools (Fig. 3). Higher transduction efficien-two- to threefold of Oz 2 cells (Table 3A), the amphotropic
equivalent of BOSC 23 cells (31). Transient titers reflect cies of NIH/3T3 cells and other cells (data not shown)
were achieved with ProPak-A supernatants, even thoughthe efficiency of transient transfection, and the titers ob-
tained with ProPak-A cells are lower than those achieved supernatants from PA317 or ProPak-A cells had similar
end-point titers (Table 3C). We have previously postu-with Oz 2 cells, possibly because Oz 2 is based on a
293T cell clone selected for high transient transfection lated that PA317-packaged vector contains a viral inhibi-
tor of transduction, possibly envelope protein (13), and itefficiency (31).
For gene therapy applications, it is necessary to gener- may be that ProPak-A supernatants contain less inhibitor.
One of our major concerns was to evaluate the safetyate large volumes of characterized supernatants, which
cannot be easily prepared by transient transfection. of the ProPak-A cells. In previous work (S. Forestell, I.
Plavec, and G. Veres, unpublished) we found that the vec-Therefore, we were more interested in determining the
stable end-point titers and the transduction efficiencies tor BC140revM10 (1) reproducibly gave rise to RCR in
PA317 cells. BC140revM10 carries the extended packag-(13). End-point titers were determined for supernatants
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TABLE 3 of retroviral gene transfer by direct administration of vec-
tor particles to human beings. In addition, targeting ofComparison of End-Point Titers from Transiently Transfected
particles bearing hybrid ligand-ecotropic envelope glyco-ProPak-A Cell Clones (A) or Stable Producer Cell Clones (B) or
Pools (C) proteins specific for cell surface molecules has been
reported (5, 17, 38). A prerequisite is that the particles
(A) Transient titers—MFG lacZ vector are not inactivated by human serum. Therefore, we ana-
lyzed the susceptibility of ProPak-A- or PA317-packagedCell line or clone End-point titer (cfu 1 1005/ml)
vector particles to inactivation by human serum. In addi-
Oz2 13.8 { 0.3 tion, we analyzed ecotropic supernatants packaged in
ProPak-A.12 8.8 { 0.8 either PE501 cells (NIH/3T3-based; 26) or 293 cells. Vec-
ProPak-A.31 8.0 { 0.5 tor particles with either envelope generated from 293
ProPak-A.6 7.5 { 0.0
cells were resistant to human serum, while supernatantsProPak-A.27 6.8 { 1.2
packaged in NIH/3T3 cells were inactivated by incuba-ProPak-A.21 6.0 { 1.0
ProPak-A.5 6.0 { 2.0 tion with human serum (Fig. 4). Takeuchi et al. (41) con-
cluded that resistance of vector particles to human serum
(B) Stable titers—LMTNL vector was determined by both the host cell type and the viral
envelope. Our data suggest that packaging of ampho-
Producer clone End-point titer (G418r cfu 1 1006/ml)
tropic and ecotropic vectors in 293-based cells is suffi-
cient to confer resistance to human complement, andPA317.LMTNL 1.7 { 0.7
ProPak-A.6.LMTNL.6 2.1 { 0.3 studies to understand this phenomenon are ongoing.
ProPak-A.6.LMTNL.7 2.2 { 0.8 The ProPak-A cells described in this study are safer
than existing packaging cell lines because they carry the
(C) Stable titers—LLySN Vector
Producer pools End-point titer (G418r cfu 1 1006/ml)
PA317.LLySN 1 1.5 { 0.3
PA317.LLySN 2 1.4 { 0.4
PA317.LLySN 3 0.9 { 0.1
ProPak-A.6. LLySN 1 1.9 { 0.5
ProPak-A.6. LLySN 2 1.6 { 0.3
Note. Supernatants were collected after 16 hr at 327, and end-point
titers determined on NIH/3T3 cells (13). cfu, colony-forming units. (A)
Cells were seeded at 2 1 105 cells/cm2 in six-well plates and
transfected 16 hr later with 2.5 mg DNA/well MFG-lacZ (8) in the pres-
ence of 25 mM chloroquine (31). Titers are the average and range for
duplicate transfections. Oz 2 cells are also called Bing cells. (B and C)
Supernatants were harvested from confluent cultures of producer cell
clones (B) or pools (C) in T-75 flasks. (C) End-point titers for superna-
tants for which transduction efficiency determinations are shown (Fig.
3). The average and range for triplicate samples are given.
ing sequence, including the ATG of the gag ORF. The
LMTNL vector (10), in contrast, lacks part of the 5* untrans-
lated region and contains no gag sequences and is there-
fore less likely to recombine and form RCR. We introduced
the BC140revM10 or LMTNL vectors into PA317 or Pro-
Pak-A cells and tested culture supernatants for RCR (14,
32) at weekly intervals. The PA317/BC140revM10 combi-
nation (transfected or transduced) gave rise to RCR detect-
able by direct inoculation of culture supernatant onto PG4
cells at 4 weeks (Table 4). Cultures were maintained for
FIG. 3. Transduction efficiencies achieved with Lyt2-encoding4 more weeks and also tested by coculture of producer
(LLySN) vector supernatants from PA317 or ProPak-A-based producercells with M. dunni cells to amplify any RCR in the culture,
cells were quantitated as the proportion (%) of NIH/3T3 cells thatfollowed by S/L0 assay on PG4 cells. Even by this strin-
stained (FACScan, Becton Dickinson) with anti-Lyt2 antibody (Phar-
gent assay for RCR, the ProPak-A-based producer pools mingen, San Diego, CA) 2 days after inoculation with the dilutions of
were all free of RCR (Table 4). vector supernatant shown. Supernatants were prepared from confluent
producer cell cultures after 12 hr at 327.Recently, interest has arisen in the in vivo application
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TABLE 4
Assay for Presence of RCR in Cultures Carrying the BC140revM10 or LMTNL Vectors
Packaging cell line Transfected with Transduced with Supernatant RCR (wk) Coculture RCR (wk 8)
ProPak-A pBC140revM10 N/A (8) Negative
ProPak-A pLMTNL N/A (8) Negative
ProPak-A N/A M(G).BC140revM10 (8) Negative
ProPak-A N/A M(G).LMTNL (8) Negative
PA317 pBC140revM10 N/A 4 Not tested
PA317 pLMTNL N/A (8) Negative
PA317 N/A M(G).BC140revM10 4 Positive
PA317 N/A M(G).LMTNL (8) Negative
Note. RCR detected by S/L- assay on PG4 cells (ATCC CRL 2032) by inoculation with supernatant from producer cell cultures, or after three
passages of coculture with Mus dunni cells. N/A, not applicable. (8), no RCR detected 8 weeks after G418-resistant pools established. M(G).,
transient MLV(VSV-G) pseudotype (45) used as inoculum.
minimum MLV sequences. The 293 cells in which we contrast to previous studies using the MLV-LTR promoter
(7, 21, 22, 28, 31), we expressed the structural proteinsestablished the ProPak-A line are devoid of sequences
that cross-hybridize with MLV and therefore no endoge- from the human CMV promoter, reducing the MLV-de-
rived sequences present in the packaging cells to a mini-nous sequences could recombine to form RCR, in con-
trast to the situation in producer cells derived from NIH/ mum. NIH/3T3-based packaging cells have been de-
scribed using a heterologous promoter (2, 40). However,3T3 cells (7, 21, 22, 28). In addition to separating gag-
pol and env genes on different expression plasmids (7, low stable titers were achieved (2) unless the episomal
plasmid copy number was amplified (40), probably be-21, 22, 28), the probability of recombination was mini-
mized by including only the ORFs and no flanking se- cause the metallothionein promoter that was used is
weaker than the CMV promoter. In practice, the ProPak-quences for the MLV gag-pol and env genes. Also, in
FIG. 4. Resistance to human serum of vector particles packaged in either murine or human cells. LacZ-encoding vector supernatants were
prepared from stable producer cells (PA317; PE501), by transient transfection of vector into packaging cells (ProPak-A), or by cotransfection of
packaging and vector constructs into 293 cells (293). Supernatants were mixed with an equal volume of a pool of human serum from five healthy
donors and incubated for 1 hr at 377, and the residual titer was determined on NIH/3T3 cells (41). The serum was either untreated (HS) or had
been heat-inactivated for 30 min at 567 (HI-HS). The human serum pool had a hemolytic titer (CH50 ; EZ Complement Assay, Diamedix, Miami, FL)
of 66 to 137 before, and 8 after heat-inactivation. End-point titers (cfu 1 1005/ml) of supernatants treated with heat-inactivated serum (100%) were
PA317, 5.0; ProPak-A, 1.0; PE501, 1.4; and 293, 1.1. The bars indicate the range for duplicate samples.
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